GHF Plus: How Geopolitics Has Reshaped Global Biomedical Investments in 2025
Newsletter Edition #293 [GHF Plus: Global Health Policy Intelligence]
Dear Readers,
We are very pleased to present our first research report this quarter on How Geopolitics Has Reshaped Global Biomedical Investments in 2025.
This is following our recent announcement on our new product GHF Plus: Global Health Policy Intelligence.
Let us know if you want to have a look and have a chat? Just hit reply to this email!
GHF Plus - our premium offering includes quarterly thematic reports with our signature analyses and insights. In addition, you can also ask us any questions you may have on the field, in a thirty-minute call with us every quarter where we are also happy to share our expertise and take you behind-the-scenes.
Find our work valuable? Consider become a paying subscriber. Tracking global health policy-making in Geneva is tough and expensive. Help us in raising important questions, and in keeping an ear to the ground. Readers paying for our work helps us meet our costs.
Gratitude to our subscribers who help us contribute to greater accountability in global health.
Best,
Priti
Feel free to write to us: genevahealthfiles@gmail.com
Find us on BlueSky: https://bsky.app/profile/genevahealthfiles.bsky.social
GHF Plus: Global Health Policy Intelligence
How Geopolitics Has Reshaped Global Biomedical Investments in 2025
An Analysis of Sectoral Shifts in Response to U.S. Tariffs, Global Supply Chain Realignments, and Post-COVID R&D Agendas
By Vivek N D
Global biopharma funding touched US $ 100 billion in 2024 according to industry estimates.
Since the beginning of President Donald Trump’s second term in January 2025, the global biomedical investment landscape has undergone a seismic shift. His administration’s renewed commitment to protectionist trade policies, particularly via the reinstatement of pharmaceutical and biotech tariffs, has catalyzed an extensive reorientation of financial and strategic priorities in the health sector. Such protectionist trade measures, combined with global economic uncertainties, post-pandemic vulnerabilities, and intensifying geopolitical frictions across the globe, have forced companies to recalibrate investment strategies across vaccines, diagnostics, therapeutics, and biologics manufacturing.
This report explores five interlocking trends in global biomedical investment: efforts to avoid U.S.-imposed tariffs, measures taken to hedge against supply chain disruptions, the resurgence of global R&D investment in mRNA technology, the European Union’s strategy to attract displaced scientific talent from the United States, and the growing role of India and Brazil, increasingly seen as stable biomedical manufacturing hubs.
